Geron Corporation Reports Third Quarter 2026 Financial Results and Recent
GERON CORP (GERN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026 Reiterated 2026 RYTELO net product revenue at the mid-t
How this was made
The 30-second read
Why it matters
The new expense guidance narrows the cost base, while revenue expectations stay within the prior range, suggesting improved profitability.
Market read
The earnings release provides fresh data for traders; the expense cut may drive short‑term price appreciation.
What to watch
Potential regulatory or reimbursement hurdles for RYTELO in Europe could limit upside.
Geron reported $60.1 million in Q3 2026 RYTELO net product revenue, reiterated revenue guidance at the mid-to-high end of the $220 million to $240 million range, and lowered its total operating expenses range to $220 million to $230 million.
RYTELO net product revenue reached $60.1 million, demand grew 10% versus Q2 2026, and the company reported net income of $1.4 million compared with a net loss of $18.4 million in the prior-year quarter. Management reiterated its revenue outlook while lowering the operating-expense range, although the discontinuation of the Phase 3 IMpactMF trial increases the company’s dependence on RYTELO in lower-risk MDS.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenue, net, three months ended September 30GAAP | $60.11M | 5% | – |
| Royalties, three months ended September 30GAAP | 76K | – | – |
| Total revenues, three months ended September 30GAAP | 60.19M | – | – |
| Cost of goods sold, three months ended September 30GAAP | 6.05M | – | – |
| Research and development, three months ended September 30GAAP | 12.71M | – | – |
| Selling, general and administrative, three months ended September 30GAAP | 35.70M | – | – |
| Restructuring charges, three months ended September 30GAAP | −71K | – | – |
| Total costs and operating expenses, three months ended September 30GAAP | 54.39M | – | – |
| Income (loss) from operations, three months ended September 30GAAP | 5.80M | – | – |
| Interest income, three months ended September 30GAAP | 3.02M | – | – |
| Interest expense, three months ended September 30GAAP | −7.21M | – | – |
| Other income (expense), net, three months ended September 30GAAP | −267K | – | – |
| Net income (loss), three months ended September 30GAAP | $1.35M | – | – |
| Basic net income (loss) per share, three months ended September 30GAAP | $ 0.00 | – | – |
| Diluted net income (loss) per share, three months ended September 30GAAP | $ 0.00 | – | – |
| Weighted-average common shares, basic, three months ended September 30GAAP | 672.3M | – | – |
| Weighted-average common shares, diluted, three months ended September 30GAAP | 674.1M | – | – |
| Product revenue, net, nine months ended September 30GAAP | $169.4M | – | – |
| Royalties, nine months ended September 30GAAP | 149K | – | – |
| Total revenues, nine months ended September 30GAAP | 169.5M | – | – |
| Cost of goods sold, nine months ended September 30GAAP | 16.98M | – | – |
| Research and development, nine months ended September 30GAAP | 49.70M | – | – |
| Selling, general and administrative, nine months ended September 30GAAP | 110.0M | – | – |
| Restructuring charges, nine months ended September 30GAAP | −622K | – | – |
| Total costs and operating expenses, nine months ended September 30GAAP | 176.0M | – | – |
| Income (loss) from operations, nine months ended September 30GAAP | −6.54M | – | – |
| Interest income, nine months ended September 30GAAP | 9.42M | – | – |
| Interest expense, nine months ended September 30GAAP | −21.5M | – | – |
| Other income (expense), net, nine months ended September 30GAAP | −350K | – | – |
| Net income (loss), nine months ended September 30GAAP | −$18.97M | – | – |
| Basic net income (loss) per share, nine months ended September 30GAAP | $ (0.03 ) | – | – |
| Diluted net income (loss) per share, nine months ended September 30GAAP | $ (0.03 ) | – | – |
| Weighted-average common shares, basic, nine months ended September 30GAAP | 670.8M | – | – |
| Weighted-average common shares, diluted, nine months ended September 30GAAP | 670.8M | – | – |
| Cash, cash equivalents, restricted cash and marketable securities, September 30, 2026GAAP | approximately $339.4 million | – | – |
| Cash, cash equivalents and restricted cash, September 30, 2026GAAP | $71.07M | – | – |
| Current marketable securities, September 30, 2026GAAP | 217.3M | – | – |
| Other current assets, September 30, 2026GAAP | 180.4M | – | – |
| Total current assets, September 30, 2026GAAP | 468.7M | – | – |
| Noncurrent marketable securities, September 30, 2026GAAP | 51.00M | – | – |
| Property and equipment, net, September 30, 2026GAAP | 1.11M | – | – |
| Deposits and other assets, September 30, 2026GAAP | 6.26M | – | – |
| Total assets, September 30, 2026GAAP | $527.1M | – | – |
| Current liabilities, September 30, 2026GAAP | $74.25M | – | – |
| Noncurrent liabilities, September 30, 2026GAAP | 226.2M | – | – |
| Stockholders’ equity, September 30, 2026GAAP | 226.7M | – | – |
| Total liabilities and stockholders’ equity, September 30, 2026GAAP | $527.1M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| RYTELO net product revenueRYTELO demand grew 10% in the third quarter 2026 compared to the second quarter 2026, while ordering accounts increased by roughly 8% to approximately 1,700. | $60.1M | 5% | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
fiscal year 2026 outlook
- RevenueRYTELO net product revenue to be at the mid-to-high end of the $220 million to $240 million range
- Operating expenses$220 million to $230 million
- NoteTotal operating expenses include non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, depreciation, and amortization.
- NoteRYTELO is expected to be available in Germany later this year and France in 2027.
What drove it
- RYTELO demand grew 10% in the third quarter 2026 compared to the second quarter 2026.
- Ordering accounts increased by roughly 8% in the third quarter 2026 to approximately 1,700.
- The company attributed the change in net income (loss) primarily to increased revenue and continued financial discipline lowering operating expenses across the company.
- Research and development expense declined primarily due to lower personnel-related expenses and lower clinical and chemistry, manufacturing, and controls costs.
- Selling, general and administrative expense declined primarily due to lower personnel-related expenses.
- Geron initiated a gated commercial launch for eligible LR-MDS patients in targeted European markets.
Concerns
- Geron discontinued the Phase 3 IMpactMF trial after the independent Data Monitoring Committee recommended discontinuation because the trial was unlikely to meet the primary endpoint of overall survival.
- The company does not expect to pursue an approval pathway for imetelstat in relapsed/refractory myelofibrosis, will not recover its investment in the trial, and is increasingly dependent on RYTELO in lower-risk MDS.
- Cost of goods sold increased primarily due to non-cash inventory-related expenses.
- Interest expense was $(7,207 ) (in thousands) for the three months ended September 30, 2026.
What to watch
- RYTELO net product revenue performance relative to the mid-to-high end of the $220 million to $240 million fiscal-year range.
- Demand growth and ordering-account expansion in U.S. community practices.
- Availability of RYTELO in Germany by the end of the year and the planned France availability in 2027.
- Execution of the gated commercial launch in targeted European markets, including pricing, reimbursement, distribution, supply chain and other operational requirements.
- Delivery of total operating expenses within the reduced $220 million to $230 million range.
Balance sheet and cash flow
- As of September 30, 2026, Geron had approximately $339.4 million in cash, cash equivalents, restricted cash and marketable securities, compared to $326.9 million as of June 30, 2026.
- Total assets were $ 527,106 (in thousands) as of September 30, 2026.
- Current liabilities were $ 74,248 (in thousands) and noncurrent liabilities were 226,163 (in thousands) as of September 30, 2026.
- The company stated that existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future.
Analysis
Geron reported $60.1 million in RYTELO net product revenue for the third quarter of 2026, with the company stating that revenue increased 5% compared to Q2 2026. Demand grew 10% sequentially and ordering accounts increased by roughly 8% to approximately 1,700. Management identified community practices as the source of increased demand growth, supporting its stated confidence in the lower-risk MDS commercial opportunity.
The company moved to net income of $1.4 million, or $0.00 per share, from a net loss of $18.4 million, or $0.03 per share, in the third quarter of 2025. Total revenues were 60,190 (in thousands) and total costs and operating expenses were 54,391 (in thousands). The company attributed the improvement in net income primarily to increased revenue and financial discipline that lowered operating expenses.
Expense control was evident in research and development expense of 12,709 (in thousands), compared with 21,070 (in thousands) in the prior-year quarter, and selling, general and administrative expense of 35,702 (in thousands), compared with 39,001 (in thousands). Cost of goods sold was 6,051 (in thousands), compared with 1,043 (in thousands), with the increase primarily attributed to non-cash inventory-related expenses. For the nine months ended September 30, the company remained at a net loss of $ (18,972 ) (in thousands), while its operating loss narrowed to (6,539 ) (in thousands).
Geron reiterated fiscal-year 2026 RYTELO net product revenue at the mid-to-high end of the $220 million to $240 million range and reduced its total operating-expense guidance to $220 million to $230 million from $230 million to $240 million. Cash, cash equivalents, restricted cash and marketable securities were approximately $339.4 million as of September 30, 2026, compared with $326.9 million as of June 30, 2026. The company also initiated a gated European commercial launch, with Germany availability expected later in 2026 and France in 2027.
The major strategic setback was the discontinuation of the Phase 3 IMpactMF trial after the Data Monitoring Committee concluded that it was unlikely to meet its overall-survival endpoint. Geron stated that there were no new safety signals that changed imetelstat’s known safety profile, but also stated it does not expect to pursue an approval pathway in relapsed/refractory myelofibrosis and is increasingly dependent on RYTELO in lower-risk MDS. The central execution items are sustaining U.S. demand and account growth, operating within the reduced expense range, and establishing European access and commercialization infrastructure.
Management, verbatim
Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.
Harout Semerjian, President and Chief Executive Officer of Geron
Outside the U.S. there is a clear opportunity for us to serve more patients and create additional value by broadening RYTELO’s access. As such, we have initiated a gated commercial launch to bring RYTELO to targeted EU markets with availability in Germany expected by the end of the year.
Harout Semerjian, President and Chief Executive Officer of Geron
Not in the filing
stated, not guessed- Non-GAAP revenue, income, earnings per share, margins, and cash flow measures were not reported.
- Gross margin was not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Capital returns, including share repurchases and dividends, were not reported.
- Tax rate was not reported.
- A debt balance was not separately reported.
- Prior-quarter figures for income statement metrics were not reported, except the stated cash, cash equivalents, restricted cash and marketable securities comparison as of June 30, 2026.
- Previous-release outlook was not provided; therefore, no actual-versus-prior-guidance comparison is included.
- Segment revenue beyond RYTELO product revenue was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Geron filed a Form 8‑K reporting its third‑quarter 2026 financial results and updated guidance.
Ticker impact
Geron reported Q3 2026 results with $60.1M RYTELO revenue and lowered operating‑expense guidance to $220‑$230M.
likely modest upside as lowered expense guidance supports profitability
The expense reduction improves margin outlook while revenue guidance remains unchanged, reducing downside risk.
Market effects
Biotech sector may see slight uplift as expense‑discipline signals better cash flow management.
U.S. biotech investors could react positively in early trading.
Limited to investors tracking hematology‑focused biotech firms.
Counterpoint
Lowered expense guidance may mask underlying demand weakness if revenue growth stalls.
Key entities
- companyGeron Corporation
Hematology‑focused biopharma reporting Q3 2026 results.
